Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer

Digestion

Volumn 83, Issue 3, 2011, Pages 146-152

  Watanabe, Masayuki ^a   Nagai, Yohei ^a   Kinoshita, Kuichi ^a   Saito, Seiya ^a   Kurashige, Junji ^a   Karashima, Ryuichi ^a   Hirashima, Kotaro ^a   Sato, Nobutaka ^a   Imamura, Yu ^a   Hiyoshi, Yukiharu ^a   Baba, Yoshifumi ^a   Iwagami, Shiro ^a   Miyamoto, Yuji ^a   Iwatsuki, Masaaki ^a   Hayashi, Naoko ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Docetaxel; Esophageal cancer; Induction chemotherapy; Neoadjuvant chemotherapy; Node positive esophageal cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UPTAKE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUTROPENIA; NODE POSITIVE ESOPHAGEAL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; TAXOIDS;

EID: 79251546723     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321797     Document Type: Conference Paper

References (27)

1. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220:364-373. (Pubitemid 24313229)
2. Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, Fujii T, Yamasaki K, Higaki K, Noake T, Ishibashi N, Mizutani K: Mortality and morbidity rates, postoperative course, quality of life and prognosis after extended radical lymphadenectomy for esoph-ageal cancer. Comparison of three-field lymphadenectomy with two-field lymphad-enectomy. Ann Surg 1995; 222: 654-662.
3. Ando N, Iizuka T, Ishida K, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 2003; 21:4592-4596.
4. Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, Nakamura T, Ozawa S, Yabusaki H, Aoyama N, Kurita A, Fukuda H: A randomized trial of postoperative chemotherapy with cisplatin and 5-fluorouracil versus neo-adjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG9907). J Clin Oncol 2008; 26(suppl 215):4510.
5. Allum W, Stenning SP, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27:5062-5067.
6. Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K, Numasaki H, Oyama T, Shinoda M, Takeuchi H, Tanaka O, Teshima T, Udagawa H, Uno T, Barron JP: Comprehensive registry of esophageal cancer in Japan, 2002. Esophagus 2010; 7:7-22.
7. Schlag PM: Randomized trial of preoperative chemotherapy for squamous cell carcinoma of the esophagus. The Chirurgische Arbeitsgemeinschaft für Onkologie der Deutschen Gesellschaft für Chirurgie Study Group. Arch Surg 1992; 127:1446-1450.
8. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S: Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96:242-248.
9. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Heller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
10. Law S, Fok M, Chow S, Chu KM, Wong J: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210-217.
11. Ancona E, Roul A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Percchia A: Only pathologic complete response to neoadjuvant chemotherapy improve the long-term survival of patients with resectable squamous cell carcinoma. Cancer 2001; 91:2165-2174.
12. Shimakawa T, Naritaka Y, Asaka S, Isohata N, Murayama M, Konno S, Yoshimatsu K, Shiozawa S, Katsube T, Ogawa K: Neoadjuvant chemotherapy (FAP) for esophageal cancer. Anticancer Res 2008; 28: 2321-2326.
13. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M, Doki Y: Tumorbudding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemot herapy. Cancer 2009; 115: 3324-3334.
14. Ilzuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992; 22:172-176.
15. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16:1826-1834.
16. Ilson DH, Saltz L, Enzinger P, Huang Y, Komblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17:3270-3275.
17. Millar J, Scullin P, Morrison A, McClory B, Wall L, Cameron D, Philips H, Price A, Dunlop D, Eatock M: Phase II study of gemcit abine and cisplatin in locally advanced/meta-static oesophageal cancer. Br J Cancer 2005; 93: 1112-1116.
18. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
19. Posner MR, Hershock DM, Blajman CR, Mickiewics E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Rarz LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio R del C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Hadda RI, TAX 324 Study Group: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715.
20. Park SR, Chun JH, Kim YW, Lee JH, Choi JS, Bae JM, Kim HK: Phase II study of low-dose docetaxel/fluorouracil/cisplatin in meta-static gastric cancer. Am J Clin Oncol 2005; 28:433-438.
21. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007; 18: 1673-1679.
22. Tebbutt N, Sourjina T, Strickl and A, Van Hazel G, Ganju V, Gibbs D, Gebski V, Munro S, Cummins M: ATTX: Randomized phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophagogastric cancer, final results of an AGITG trial. J Clin Oncol 2007; 25(suppl 18S):4528.
23. Ajani JA, Phan A, Ho L, Tetzlaff ED, Baker J, Wei Q: Phase I/II trial of docetaxel plus ox-aliplatin and 5-fluorouracil (D-FOX) in patients with untreated advanced gastric or gastroesophageal cancer. J Clin Oncol 2007; 25(suppl 18S):4612.
24. Al-Batran SE, Hartmenn JT, Hofheinz R, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jager E: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with met-astatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische On kologie. Ann Oncol 2008; 19: 1882-1887.
25. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A: Weekly docetaxel, cisplatin, and 5-fluoro-uracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 2010; 116: 1446-1453.
26. Brücher BLDM, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M: Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233: 300-309. (Pubitemid 32187807)
27. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2008; 24:4692-4698.